These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 30236024)

  • 1. Rapid complete remission of metastatic melanoma after first-line treatment with nivolumab plus tumor-infiltrating lymphocytes.
    Zhao L; Yang Y; Li W; Han L; Lin H; Gao Q
    Immunotherapy; 2018 Sep; 10(13):1133-1136. PubMed ID: 30236024
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Unresectable Non-metastatic Primary Melanoma: Complete Remission Following Treatment with Anti-Programmed-cell-death-receptor 1.
    Lheure C; Hoffmann C; Kramkimel N; Plée J; Franck N; Vanhaecke C; Goldman-Lévy G; Bataillon G; Damotte D; Dupin N; Aractingi S; Grange F; Guégan S
    Acta Derm Venereol; 2019 Jan; 99(1):107-108. PubMed ID: 30176045
    [No Abstract]   [Full Text] [Related]  

  • 3. Severe colitis after PD-1 blockade with nivolumab in advanced melanoma patients: potential role of Th1-dominant immune response in immune-related adverse events: two case reports.
    Yoshino K; Nakayama T; Ito A; Sato E; Kitano S
    BMC Cancer; 2019 Oct; 19(1):1019. PubMed ID: 31664934
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and Safety of Nivolumab in Patients With BRAF V600 Mutant and BRAF Wild-Type Advanced Melanoma: A Pooled Analysis of 4 Clinical Trials.
    Larkin J; Lao CD; Urba WJ; McDermott DF; Horak C; Jiang J; Wolchok JD
    JAMA Oncol; 2015 Jul; 1(4):433-40. PubMed ID: 26181250
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Complete Remission of Metastatic Melanoma of the Scalp Following Treatment With Nivolumab Plus Relatlimab.
    McMinn ME; Brister KA; Orr WS; Sheehan NT; Christopher WO
    Am Surg; 2024 Aug; 90(8):2078-2079. PubMed ID: 38553440
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Age-associated changes in the immune system may influence the response to anti-PD1 therapy in metastatic melanoma patients.
    Kasanen H; Hernberg M; Mäkelä S; Brück O; Juteau S; Kohtamäki L; Ilander M; Mustjoki S; Kreutzman A
    Cancer Immunol Immunother; 2020 May; 69(5):717-730. PubMed ID: 32036449
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evidence for Efficacy of Treatment With the Anti-PD-1 Mab Nivolumab in Radiation and Multichemorefractory Advanced Penile Squamous Cell Carcinoma.
    Trafalis DT; Alifieris CE; Kalantzis A; Verigos KE; Vergadis C; Sauvage S
    J Immunother; 2018; 41(6):300-305. PubMed ID: 29642086
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Case Report: Sustained Remission Due to PD-1-Inhibition in a Metastatic Melanoma Patient With Depleted B Cells.
    Wulfken LM; Becker JC; Hayajneh R; Wagner AD; Schaper-Gerhardt K; Flatt N; Grimmelmann I; Gutzmer R
    Front Immunol; 2021; 12():733961. PubMed ID: 34675925
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcomes of Adoptive Cell Transfer With Tumor-infiltrating Lymphocytes for Metastatic Melanoma Patients With and Without Brain Metastases.
    Mehta GU; Malekzadeh P; Shelton T; White DE; Butman JA; Yang JC; Kammula US; Goff SL; Rosenberg SA; Sherry RM
    J Immunother; 2018 Jun; 41(5):241-247. PubMed ID: 29672342
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tissue Harvesting for Adoptive Tumor Infiltrating Lymphocyte Therapy in Metastatic Melanoma.
    Zippel D; Friedman-Eldar O; Rayman S; Hazzan D; Nissan A; Schtrechman G; Markel G; Schachter J; Itzhaki O; Besser MJ
    Anticancer Res; 2019 Sep; 39(9):4995-5001. PubMed ID: 31519606
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Are patients in haemodialysis good candidates for immunotherapy treatment?
    Fernandez-Diaz AB; Cunquero-Tomas AJ; Garcia-Medina A; Ferrer-Guillen B; Berrocal A
    Melanoma Res; 2019 Oct; 29(5):553-555. PubMed ID: 31464825
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The forgotten role of adjuvant immune checkpoint inhibitors in preventing melanoma brain metastasis.
    El Rassy E; Farhat F; Kattan J
    Immunotherapy; 2018 Nov; 10(15):1289-1291. PubMed ID: 30474477
    [No Abstract]   [Full Text] [Related]  

  • 13. [Principles of adoptive cell therapy based on "Tumor Infiltrating Lymphocytes"].
    Martins F; Orcurto A; Michielin O; Coukos G
    Rev Med Suisse; 2016 May; 12(519):989-93. PubMed ID: 27424426
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Complete responses to two different anti-PD1 agents in a metastatic melanoma patient.
    Kilickap S; Guven DC; Aktepe OH; Aktas BY; Dizdar O
    J Oncol Pharm Pract; 2020 Mar; 26(2):496-499. PubMed ID: 31256744
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nivolumab-induced vitiligo in a metastatic melanoma patient: A case report.
    Edmondson LA; Smith LV; Mallik A
    J Oncol Pharm Pract; 2017 Dec; 23(8):629-634. PubMed ID: 27609337
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-Lasting Complete Responses in Patients with Metastatic Melanoma after Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes and an Attenuated IL2 Regimen.
    Andersen R; Donia M; Ellebaek E; Borch TH; Kongsted P; Iversen TZ; Hölmich LR; Hendel HW; Met Ö; Andersen MH; Thor Straten P; Svane IM
    Clin Cancer Res; 2016 Aug; 22(15):3734-45. PubMed ID: 27006492
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nivolumab (OPDIVOO) BRAF V600 mutation-negative metastatic or inoperable melanoma: survival advantage.
    Prescrire Int; 2016 Dec; 25(177):289-292. PubMed ID: 30758924
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cascading adoptive cell therapy for metastatic melanoma.
    Su X; Zhang L; Wu S; Jin L; Ye J; Guan Z; Chen R
    Cancer Biother Radiopharm; 2011 Jun; 26(3):401-6. PubMed ID: 21711116
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of the Tumor Reactivity of Tumor-Infiltrating Lymphocytes in a Metastatic Melanoma Lesion that Lost Major Histocompatibility Complex Class I Expression after Anti-PD-1 Therapy.
    Inozume T; Yaguchi T; Ariyasu R; Togashi Y; Ohnuma T; Honobe A; Nishikawa H; Kawakami Y; Kawamura T
    J Invest Dermatol; 2019 Jul; 139(7):1490-1496. PubMed ID: 30684558
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of nivolumab in melanoma.
    Gomes F; Serra-Bellver P; Lorigan P
    Future Oncol; 2018 Jun; 14(13):1241-1252. PubMed ID: 29328782
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.